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Background: Patients with underlying cardiovascular disease and Coronavirus disease 2019 
(COVID-19) infection are at increased risk of morbidity and mortality. However, there is 
limited information on management and outcomes of patients presenting with acute coronary 
syndrome (ACS) and concomitant COVID19 infection.  
Objectives: This multisource national analysis of live data from England was designed to 
characterise the presenting profile and outcomes of patients hospitalized with ACS and 
COVID-19 infection.  
Methods: Multisource data from all acute NHS hospital in England was linked to study the 
characteristics and outcomes of patients hospitalized with COVID-19 ACS compared to non 
COVID-19 ACS patients. Hierarchical multilevel models were constructed to study the 
association between COVID19 ACS and in-hospital and 30-day mortality.  
Results: Between 1st March 2020 and 31st May 2020, 517 (4.0%) were admitted with 
COVID- 19 ACS from a total of 12,958 ACS patients.  COVID-19 ACS patients were 
generally older, BAME ethnicity, more comorbid and had unfavourable presenting 
characteristics compared to non-COVID-19 ACS patients. They were less likely to receive 
invasive coronary strategy in the form of coronary angiography (67.7% vs 81.0%), PCI 
(30.2% vs 53.9%), dual antiplatelet medication 76.3% vs 88.0%), and other important 
secondary medication. Patients with COVID-19 ACS had higher in-hospital (aOR 3.27 
95%CI 2.41-4.42) and 30-day mortality (aOR 6.53 95%CI 5.1-8.36) compared to non 
COVID-19 ACS group.    
Conclusion: COVID-19 infection is prevalent but less frequent in the patients hospitalized 
with ACS in England. Presence of COVID-19 infection in patients with ACS is associated 
with significant mortality hazard. 
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 Introduction: 
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2), has affected more than 17 million people resulting in almost 
700,000 deaths worldwide1. Although, COVID-19 patients predominantly present with 
respiratory symptoms, various extra-pulmonary manifestations including thrombotic events, 
myocardial injury and ischaemia, acute kidney injury and cardiac arrhythmias have also been 
reported 2, 3. 
Acute coronary syndrome (ACS) in the context of viral infection may be related to 
atherosclerotic plaque rupture precipitated by endothelial cell damage, a cytokine storm and a 
heightened inflammatory state4 Furthermore, admission with an ACS during the COVID-19 
pandemic in which large numbers of patients were hospitalised with COVID-19, may 
increase the risk of nosocomial transmission of COVID-19 in this vulnerable patient group.  
The management of patients presenting with suspected ACS in the context of 
COVID19 remains a challenge7. There are limited data regarding the clinical characteristics, 
management strategies and post-discharge mortality of patients hospitalized with a diagnosis 
of ACS and concomitant COVID-19 infection7. Small case series of 18 and 28 patients 
presenting with ST-elevation acute myocardial infarction (STEMI) and concomitant COVID-
19 infection have reported significant variability in presenting characteristics and in-hospital 
survival of these patients 8, 9. These reports lacked data around clinical presentation, 
pharmacological treatments and post-discharge survival. Fewer data are available from a 
national, or from a broader ACS perspective including non-ST-elevation myocardial 
infraction (NSTEMI). Such information could prove useful in order to devise optimal 
pathways of care in the event of a second wave of COVID-19. 
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This study, using high resolution, multisource contemporary national data from England, 
systematically profiles the presenting and procedural characteristics, in-hospital and 30-day 
mortality in patients admitted with a suspected diagnosis of ACS and concomitant COVID-19 
infection. The primary aim was to investigate the in-hospital and 30-day all-cause mortality 
in patients hospitalized with COVID-19 ACS diagnosis compared with those without 
COVID-19 ACS. The second aim was to describe the differences in management and 
independent predictors of 30-day mortality of those with COVID-19 ACS. 
Methods 
Study data 
An unselected, real-world cohort of all patients hospitalized with a suspected diagnosis of 
ACS in England was derived by linking patient records across four different sources of data, 
namely Hospital Episode Statistics (HES), the Myocardial Ischaemia National Audit Project 
(MINAP), the British Cardiovascular Intervention Society (BCIS) percutaneous coronary 
intervention registry and Civil Registration Death data. The full details about the validity, 
strengths, limitations and utility for research purposes have been described previously10-12. 
Briefly, HES contains International Statistical Classification of Disease-10th Revision (ICD-
10) clinical, geographic, administrative and patient information of all patients hospitalized in 
any National Health Service (NHS) hospital in England10. MINAP is an exclusive ACS 
registry designed to collect information across 130 data fields about patient demographics, 
use of various pharmacological and invasive treatments and in-hospital care of patients 
hospitalized with a suspected diagnosis of ACS (type 1 myocardial infarction) in any NHS 
acute care hospital in England12. Similarly, almost over 98% of the PCI activity in England is 
captured in the BCIS PCI registry, which is designed to collect detailed procedural and 
clinical data of all patients undergoing PCI11. Finally, the civil registration of death register 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted August 22, 2020. .https://doi.org/10.1101/2020.08.20.20175091doi: medRxiv preprint 
holds the mortality information of all deaths in England. All patient records in these datasets 
can be identified using a unique 10-digit number. For the purposes of this study we used live 
reporting data from all hospitals in England submitting their data to these respective registries 
during the COVID-19 pandemic.  
Ethical approval 
This study was conducted under the endorsement of the Chief Scientific Advisor to the UK 
government and Scientific Advisory Group for Emergencies (SAGE). The access to the data 
was granted under the Health and Social Care State Secretary’s notice issued under 
Regulation 3(4) of the NHS (Control of Patient Information Regulations) 2002 (COPI) to 
NHS Digital, allowing NHS Digital to share confidential patient information with 
organisations entitled to process this under COPI for COVID-19 purposes. Furthermore, 
MINAP and BCIS data are collected and hosted by the National Institute of Cardiovascular 
Research (NICOR) and used for audit and research purposes without formal individual 
patient consent under section 251 of the NHS Act 200613-16. The study complies with the 
Declaration of Helsinki. 
Study cohort 
The analytical cohort for this study consisted of consecutive patients aged ≥18 years 
hospitalized with a suspected diagnosis of ACS in England and documented within the 
MINAP registry, between 1st March 2020 to 31st May 2020. The COVID-19 status 
information for all patients was derived from HES using ICD-10 codes ‘U071’ (confirmed) 
and ‘U072’ (suspected) and linked with the MINAP record of the same patient matching 
across the two datasets based on their unique NHS number and admission date. In the second 
step, the records of all these patients were linked across to the records in the BCIS PCI 
registry using the same NHS number and admission week. Finally, the mortality information 
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of all patients was tracked within 30 days beyond discharge or up to 10th July 2020 from the 
Civil registration of Death register. Supplementary figure 1 illustrates the cohort selection 
and data linkage steps of all patients in the study.  
Final study data contained comprehensive detailed information about patient demographics, 
COVID-19 status, clinical characteristics, comorbidities, pre-hospital and in-hospital 
pharmacological treatments, cardiac investigations, invasive coronary procedures, procedural 
characteristics and complications. Patients with missing or invalid NHS number and date of 
admission were excluded from the analysis. Patients with valid diagnosis codes of COVID-19 
captured in the HES data were defined as the “COVID-19 ACS” group whilst all other ACS 
patients were defined as the “non COVID-19 ACS” group. Time to reperfusion therapy for 
STEMI was calculated from time of admission to time of receipt of reperfusion treatment 
where time of admission was defined as time of arrival into hospital. The primary outcomes 
of interest were in-hospital and 30-day mortality in ‘COVID-19 ACS’ compared with ‘non 
COVID-19 ACS’ patients. 
Statistical analysis 
Baseline characteristics were reported as number and percentages for categorical variables, 
means with standard deviation or median with interquartile ranges for continuous data. 
Statistical differences between the two groups were obtained using Chi-Square test or t-test or 
Kruskal-Wallis tests as appropriate. The daily counts of COVID-19 positive ACS patients 
were presented using a simple daily moving average from 1st March 2020 up to and 
including 31st May 2020, adjusted for seasonality. Multiple imputations using chained 
equation (MICE) techniques were used to impute missing values in all the study variables. 
Each of the imputation models included all the other variables used in the analyses as 
reported in the online supplement (Supplementary Table 1). Linear regression for continuous 
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variables, multinomial for nominal variables, ordinal logistic regression for ordered factors 
and logistic regression models for binary variables were used to generate 10 imputed datasets 
and all subsequent analyses were performed on these and results were pooled using Robin’s 
rule17, 18.  
To study the association between ‘COVID-19 ACS’ status and clinical outcomes, hierarchical 
logistic regression models with random intercept were constructed. The hospital ID was used 
as a random intercept to account for nesting of patients within the different hospitals. All 
models were adjusted for age, sex, ethnicity, body mass index, presenting characteristic 
(blood pressure, heart rate, cardiac arrest, clinical syndrome, creatinine, Kilip class, left 
ventricular systolic function), cardiovascular comorbidities (previous PCI, previous CABG, 
previous AMI, previous cerebrovascular event, peripheral vascular disease, renal dysfunction, 
heart failure, hypercholesterolemia, angina, diabetes, smoking status, asthma or chronic 
obstructive airway disease and family history of coronary heart disease), in-hospital 
pharmacology (low molecular weight heparin, unfractionated heparin, warfarin, loop diuretic, 
glycoprotein IIb/IIIa inhibitor), discharge pharmacology (dual antiplatelet medication use, 
statin, angiotensin converting enzyme (ACE) or angiotensin receptor blocker use), receipt of 
coronary angiography or PCI and cardiology care. For patients undergoing PCI, the 
association between ‘COVID-19 ACS’ status and mortality was estimated by constructing 
separate models adjusting all the procedural information reported in table 3 and in addition to 
the aforementioned confounders. The independent predictors of 30-day mortality were 
studied using multivariable logistic regression model. All tests were two-sided and statistical 
significance considered as P<0.05. Statistical analyses were performed in Stata MP 16.0 
College station, Texas, US via secure remote access on the NHS Digital servers hosting all 
the datasets. 
Results:  
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Between 1st March and 31st May 2020, 12,958 patients were hospitalized with ACS in 
England, of which 517 (4.0%) were COVID-19 positive. There was a steady increase in the 
number of daily COVID-19 ACS hospitalizations during March, reaching a peak in the first 
week of April followed by a steady decline by the end of May (Figure 1). Higher proportions 
of daily COVID-19 ACS cases were admitted with a suspected NSTEMI compared to 
STEMI throughout the study period.   
Patient characteristics 
Patients in the COVID-19 ACS group were older compared with the non COVID-19 ACS 
group (72.8 year vs 67.0 year), and a greater proportion were from Black, Asian and Ethnic 
minority origin (20.2% vs 12.8%), they had a lower body mass index (26.9 vs 28.2) and more 
likely to be hospitalized with NSTEMI (67.0% vs 62.0%). The COVID-19 ACS group also 
exhibited an increased incidence of in-hospital cardiac arrest (6.3% vs 3.0%), higher troponin 
levels, and were more likely to have presented in pulmonary oedema (9.0% vs 3.4%) or 
cardiogenic shock (9.6% vs 3.9%). They had a higher prevalence of heart failure (23.7% vs 
13.4%), cerebrovascular disease (15.7% vs 8.0%), insulin treated diabetes (13.6% vs 7.5%) 
and hypertension (69.4% vs 58.3%).  
Out of 12,958 patients, 6,864 (53.0%) underwent PCI and were successfully linked from 
MINAP into the BCIS registry (supplementary figure 1). COVID-19 ACS patients 
undergoing PCI were of similar age and had similar baseline characteristics to the overall 
ACS cohort (Table 2). The angiographic and procedural profiles of COVID-19 ACS patients 
(such as number of lesions attempted, vessels attempted, multivessel PCI, number of stents 
used, use of intracoronary imaging such as IVUS, OCT and pressure wire use) were similar 
to the non COVID-19 ACS cohort undergoing PCI. From the patients who didn’t receive 
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PCI, the proportions of angiographically normal coronaries or surgical disease were similar in 
both non COVID-19 and COVID-19 ACS groups.  
Discharge medication and Guidelines-indicated care 
Patients in the COVID-19 ACS group were less likely to receive optimal secondary 
prevention medication such as aspirin (90.5% vs 94.5%), dual anti-platelet medications 
(76.3% vs 88.0%), statin (89.1% vs 95.1%) and ACE/ARB (80.4% vs 88.6%) therapy 
compared with the non COVID-19 ACS group. Overall, only one third (30.2% vs 53.9%) of 
COVID-19 ACS patients received PCI compared to non COVID-19 ACS patients. COVID-
19 NSTEMI patients were also less likely to undergo invasive coronary angiography (67.7% 
vs 81.0%) and PCI (22.2% vs 46.0%) compared to the non COVID-19 NSTEMI cohort.  
The median time from in-hospital arrival to reperfusion for patients presenting with STEMI 
was 13.2 minutes longer in the COVID-19 STEMI group compared with the non COVID-19 
STEMI group. COVID-19 NSTEMI group also experienced delays in time to coronary 
angiography (38.1 hours vs 33.7 hours) compared with non COVID-19 NSTEMI group. Less 
than half of the COVID-19 ACS group were referred to the cardiac rehabilitation programme 
(42.9% vs 75.9%) or had cardiology follow-up arranged following discharge from the 
hospital (73.9% vs 87.1%).  
Clinical outcomes and predictors of mortality  
In the MINAP cohort, the COVID-19 ACS group had higher in-hospital (24.2% vs 5.1%) and 
30-day mortality rates (41.9% vs 7.2%) compared with the non COVID-19 ACS cohort. After 
adjustment for baseline differences in demographics, presenting characteristics, comorbidities 
and pharmacology, the hierarchical multi-level logistic regression model showed a 
significantly higher risk of in-hospital (adjusted odds ratio 3.27 95%CI 2.41-4.42) and 30-day 
mortality (adjusted odd ratio 6.53 95%CI 5.12-8.36) in the COVID-19 ACS patients 
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compared with non COVID-19 ACS patients (Figure 2). In the subgroup analysis stratified 
according to type of ACS, although short term mortality was similar between the NSTEMI 
and STEMI groups, the NSTEMI group had higher mortality rates (adjusted odds ratio 8.45 
95%CI 6.03-11.83) at 30-days. Similar, higher mortality rates were observed in COVID-19 
ACS patients undergoing PCI compared with non COVID-19 ACS patients undergoing PCI. 
The multilevel regression model showed that increasing age per year, severe LVSD, in-
hospital cardiac arrest, peak troponin concentration levels, renal dysfunction and use of 
ACE/ARB on discharge were strong independent risk factors for 30-day mortality in the 
COVID-19 ACS group (Figure 3).  
Discussion 
This multisource, national report of contemporary data from all ACS related hospitalizations 
in England during the COVID-19 period provides detailed information about the risk profile, 
clinical care and outcomes of ACS patients with COVID-19 infection. Specifically, COVID-
19 ACS group had over 6-fold increase in mortality within 30 days compared with non 
COVID-19 ACS and were less frequently prescribed appropriate secondary prevention 
medications. They were older, more likely to be of BAME origin, had more comorbid 
features and exhibited high risk presenting characteristics such as higher Killip class, 
troponin concentrations, creatinine and evidence of LV systolic dysfunction.  
A significant knowledge gap exists in the literature about incidence and profile of ACS 
patients with concomitant COVID-19 diagnosis, and their associated clinical outcomes. We 
report that COVID-19 infection in patients presenting with ACS is prevalent at a low level in 
a national cohort of patients. The higher prevalence of pulmonary oedema and shock at 
presentation, together with the higher troponin concentrations levels in the COVID-19 ACS 
cohort are suggestive of increased myocardial injury in this group corroborating findings 
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from China and US cohorts19, 20. However, contrary to earlier small case series from New 
York and Italy8, 9, 21, the angiographic characteristics of COVID-19 ACS patients were not 
different from the non COVID-19 ACS patients, with a very small prevalence of non-
obstructive coronary disease and similar procedural success.  
Whilst previous studies have reported the incidence on myocardial injury based on cardiac 
biomarker levels in patients hospitalized with a confirmed COVID-19 diagnosis19, 20, none 
reported on management and outcomes of ACS patients with concomitant COVID-19 
diagnosis in a national, unselected cohort of suspected type 1 myocardial infarction. The 
management of ACS patients during the COVID-19 pandemic is based on expert clinical 
guidance which lacks consensus on the optimal treatment strategies for patients presenting 
with ACS during the COVID-19 outbreak22-25. The Chinese Cardiac Society consensus 
statement proposed medical management for the majority of patients presenting with non-ST-
elevation myocardial infarction (NSTEMI), and thrombolysis in those presenting with 
STEMI during the COVID-19 pandemic22. In contrast, the North America and Canadian 
guidelines recommended use of thrombolysis as an alternative to primary PCI for patients 
with STEMI particularly where PCI services are restricted due to COVID-19 23, 25. However, 
a joint statement from British Cardiovascular Society, BCIS and NHS England in the UK 
recommended that primary PCI should remain the default treatment for all STEMI, except in 
unusual circumstances26. In keeping with this national recommendation, we observed almost 
negligible use of thrombolysis for STEMI in the UK during the acute phase of the COVID-19 
pandemic. By contrast, there were significant differences in the care of COVID-19 ACS 
patients in that only a third of COVID-19 ACS patients received PCI, they experienced 
greater delays in reperfusion treatment or an invasive strategy and had a significantly lower 
uptake of secondary prevention medications on discharge. Given that COVID-19 ACS 
patients presented with more complex, high risk features, there is an urgent need to develop 
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effective treatment pathways to align their care with guideline recommendations 27, 28. For 
patients hospitalized with suspected ACS, especially with elevated cardiac troponin minor 
ECG changes, an immediate COVID-19 testing should be advocated in the current climate.  
 In the outcomes analysis, COVID-19 ACS patients had a poor prognosis compared 
with the non COVID-19 ACS patients. One of four patients died in hospital with an over six-
fold higher 30-day mortality in the overall cohort as well as those undergoing PCI. Although 
we didn’t have information regarding the presenting COVID-19 symptoms or respiratory 
complications in this cohort, we noted significantly higher levels of peak troponin, creatinine, 
a lower presenting blood pressure and tachycardia in this cohort. Troponin elevation three 
times the upper reference limit is known to be associated with worse in-hospital outcomes in 
COVID-19 patients19, 20. It remains unclear whether the rise in cardiac biomarkers is related 
to viral myocarditis5, 6 or plaque rupture secondary to virus-induced inflammatory response29-
31
 or a type 1 AMI. In this cohort of suspected type 1 myocardial infarction, there was a low 
prevalence of non-obstructive coronary disease and the angiographic characteristics and 
procedural management of the COVID-19 ACS were similar to the non COVID-19 ACS 
group. We observed higher rates of COVID19 infection and subsequent 30-day morality in 
NSTEMI compared with STEMI. Patients presenting with NSTEMI are generally older, more 
comorbid and less likely to present early during the COVID-19 pandemic which in 
conjunction with increased infection rates may be responsible for their poor outcomes.  
The COVID-19 ACS cohort were also less frequently prescribed low molecular weight or 
unfractionated heparin and statins. Patients with acute COVID-19 are known to be at 
increased risk of thromboembolic complications and are therefore likely to benefit from 
appropriate anticoagulation to reduce thrombus burden and statins to stabilize plaque. In the 
risk factor analysis, elevated creatinine, peak troponin, heart rate, left ventricular systolic 
dysfunction and use of ACE inhibitor or ARBs were strong independent risk factors for 30-
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day mortality in this report. Although recent data have negated earlier concerns of an 
increased risk of adverse outcomes in COVID-19 patients with use of ACE inhibitors or 
ARBs, further research is required to establish the role of these medications in patients 
presenting with COVID-19 ACS32, 33. Patients hospitalized with ACS and concomitant 
COVID-19 infection may also be focus of specific anti-viral drug trials or 
immunosuppression therapy to establish the benefit of these therapies in this high risk 
cohort7.  
The interrogation of multisource, multihospital live data from England has given 
insight in to the presenting characteristics, risk profile, treatment strategies and 30-day 
mortality in an unselected cohort of patients hospitalized with COVID-19 ACS. However, 
there are some study limitations which must be kept in mind whilst interpreting these 
findings. First, the COVID-19 diagnosis was based on the ICD-10 codes and so it is unclear 
whether the diagnosis at the hospital was made on clinical grounds or using a formal 
polymerase chain reaction (PCR) test, and the timing of the tests leading to the diagnosis is 
unclear. Moreover, other suspected ACS patients were not routinely tested at the start of the 
pandemic and we cannot say how many might have been carrying the virus, although the lack 
of a COVID-19 code suggests they did not have a clinical syndrome related to the virus. 
Second, information around COVID-19 symptoms, their duration and other organ 
involvement is not captured in the datasets used in this analysis, and hence it difficult to 
ascertain whether patients had COVID-19 symptoms followed by an ACS or vice versa, and 
whether COVID-19 infection occurred in the hospital or the community. Third, whilst the 
MINAP registry is the UK national ACS registry for suspected type1 AMI, we cannot rule 
out misclassification bias from misdiagnosis of myocarditis or type 2 AMI, although only a 
small proportion of cases that underwent angiography had non-obstructive coronary artery 
disease. 
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Conclusion 
COVID-19 infection was present in 4% of patients hospitalized with a suspected ACS in 
England during the study period. It was associated with worst outcomes independent of the 
type of ACS, however higher 30-day mortality was observed in NSTEMI group compared 
with STEMI group. Elderly, comorbid and BAME patients with underlying cardiovascular 
disease are more likely to acquire COVID-19 infection and often present with unfavourable 
presenting characteristics. These findings highlight the need to develop strategies for an 
efficient and equitable care for COVID ACS patients. 
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 Table 1: Baseline characteristics COVID19 ACS compared to non COVID19 ACS patients in 
the MINAP registry 
Variables Non COVID19 ACS N=12,441 
COVID19 ACS 
N= 517 
 
P value 
Age, years mean (SD) 67.0 (13.3) 72.8 (13.9) <0.001 
Male (%) 8587 (69.1%) 352 (68.1%) 0.63 
BMI mean (SD) 28.2 (5.5) 26.9 (5.6) <0.001 
Ethnicity   <0.001 
Whites 9290 (87.2%) 360 (79.8%)  
BAME  1359 (12.8%) 91 (20.2%)  
Presenting Characteristics 
   
Heart rate, bpm, mean (SD) 79.9 (19.9) 86.7 (22.9) <0.001 
Systolic blood pressure, mean (SD) 140.7 (27.5) 134.7 (29.9) <0.001 
Cardiac arrest    <0.001 
Pre hospital cardiac arrest 434 (3.7%) 17 (3.5%)  
In- hospital cardiac arrest  349 (3.0%) 31 (6.3%)  
Clinical syndrome   0.02 
STEMI 4403 (38.0%) 153 (33.0%)  
NSTEMI 7176 (62.0%) 311 (67.0%)  
Peak troponin levels (median, IQR)    
Troponin T  99 (13-685) 380 (63.7-20.45) 0.002 
Troponin I  399 (48.9-4036) 431 (109-3396) 0.83 
Highly sensitive troponin T  231 (55-1149) 245 (41-946) 0.61 
Highly sensitive troponin I 482 (53-4193) 853 (144-4374) 0.04 
Creatinine, mean (SD) 94.9 (62.4) 134.2 (115.2) <0.001 
Kilip Class 
  
<0.001 
No heart failure 9114 (84.0%) 280 (60.0%)  
Basal crepitation 952 (8.8%) 100 (21.4%)  
Pulmonary oedema 368 (3.4%) 42 (9.0%)  
Cardiogenic shock 421 (3.9%) 45 (9.6%)  
LV systolic function 
  
<0.001 
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Good 4593 (46.1%) 132 (30.3%)  
Moderate 2665 (26.8%) 110 (25.3%)  
Poor 838 (8.4%) 59 (13.6%)  
Not assessed 1861 (18.7%) 134 (30.8%)  
Comorbidities 
   
Percutaneous coronary intervention 2077 (19.5%) 71 (15.1%) 0.02 
Coronary artery bypass graft 746 (7.1%) 39 (8.3%) 0.32 
Heart failure 1419 (13.4%) 112 (23.7%) <0.001 
Hypercholesterolemia 4439 (40.8%) 183 (39.0%) 0.43 
Angina 2004 (19.2%) 83 (17.8%) 0.47 
Cerebrovascular disease 848 (8.0%) 74 (15.7%) <0.001 
Myocardial infarction  2747 (25.5%) 136 (28.6%) 0.13 
Peripheral vascular disease 560 (5.3%) 31 (6.6%) 0.22 
Chronic kidney disease 884 (8.4%) 112 (23.7%) <0.001 
Diabetes   <0.001 
Not diabetic  8547 (73.9%) 298 (60.3%)  
Diet controlled 513 (4.4%) 31 (6.3%)  
Oral medications 1635 (14.1%) 98 (19.8%)  
Insulin therapy 868 (7.5%) 67 (13.6%)  
Hypertension 6474 (58.3%) 335 (69.4%) <0.001 
Smoking status 
  
<0.001 
Never smoked 3965 (37.6%) 152 (43.1%)  
Previous smoker 3584 (34.0%) 150 (42.5%)  
Current smoker 3003 (28.5%) 51 (14.4%)  
Asthma / COPD 1753 (16.8%) 95 (20.3%) 0.04 
Family history of CHD 2430 (27.8%) 51 (14.4%) <0.001 
In-hospital Pharmacology 
   
LMWH/UFH 6261 (72.7%) 219 (59.7%) <0.001 
Warfarin 268 (3.1%) 17 (4.6%) 0.11 
Loop Diuretic 1801 (21.1%) 166 (45.0%) <0.001 
Glycoprotein IIbIIIa inhibitor use 1147 (12.5%) 36 (9.1%) 0.04 
Discharge Pharmacology  
   
Aspirin  10951 (94.5%) 428 (90.5%) <0.001 
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Any P2Y12 Inhibitor 10552 (92.8%) 387 (84.1%) <0.001 
Dual Antiplatelet medications 9874 (88.0%) 345 (76.3%) <0.001 
Statin 9892 (95.1%) 343 (89.1%) <0.001 
ACEi / ARB 9195 (88.6%) 304 (80.4%) <0.001 
Processes of Care and Clinical outcomes    
Seen by cardiologist 11436 (97.2%) 445 (90.4%) <0.001 
Percutaneous coronary intervention  6708 (53.9%) 156 (30.2%) <0.001 
Why no PCI    <0.002 
Angiographically normal coronaries  319 (4.8%) 4 (1.7%)  
PCI inappropriate  356 (5.4%) 22 (5.8%)  
Surgical disease 135 (2.0%) 4 (1.8%)  
Coronary angiography in NSTEMI 5,259 (88.2%) 107 (68.5%) <0.001 
PCI in NSTEMI 3,299 (46.0%) 69 (22.2%) <0.001 
Time to reperfusion for STEMI, hours 
median IQR 0.76 (0.50-1.27) 0.98 (0.65-1.52) <0.001 
Call for help , hour median (IQR) 1.45 (0.47-5.3) 2.0 (0.40-6.8) 0.26 
Time to coronary angiography, hour 
median (IQR) 33.7 (14.4-128.8) 38.1 (18.3-70.8) <0.01 
Referral for cardiac Rehabilitation  8204 (75.9%) 192 (42.9%) <0.001 
Cardiology follow up 8018 (87.1%) 221 (73.9%) <0.001 
In-hospital mortality  592 (5.1%) 114 (24.2%) <0.001 
30-day mortality  843 (7.2%) 207 (41.9%) <0.001 
 
Table 2: Clinical characteristics of COVID19 ACS compared to non COVID19 ACS patients 
undergoing PCI in the BCIS registry  
 
Variables 
Non COVID19 ACS 
N=6708 
COVID19 ACS 
N= 156 
 
P value 
Age, years mean (SD) 64.4 (12.0) 65.3 (12.5) 0.38 
Male (%) 5019 (74.9%) 118 (75.6%) 0.84 
BMI mean (SD) 28.5 (5.2) 27.9 (4.8) 0.17 
Ethnicity   <0.001 
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Whites 5045 (85.5%) 104 (72.7%)  
BAME  853 (14.5%) 39 (27.3%)  
Presenting Characteristics 
   
Heart rate, bpm, mean (SD) 78.1 (18.4) 83.8 (20.9) <0.001 
Systolic blood pressure, mean (SD) 140.3 (27.1) 137.1 (31.5) 0.18 
Cardiac arrest    <0.001 
Pre hospital cardiac arrest 274 (4.3%) 9 (6.2%)  
In- hospital cardiac arrest  179 (2.8%) 14 (9.7%)  
Clinical syndrome   0.21 
STEMI 3394 (50.7%) 87 (55.8%)  
NSTEMI 3299 (49.3%) 69 (44.2%)  
Creatinine, mean (SD) 89.2 (53.0) 114.6 (105.2) <0.001 
Kilip Class 
  
<0.001 
No heart failure 5224 (87.8%) 95 (66.0%)  
Basal crepitation 336 (5.6%) 18 (12.5%)  
Pulmonary oedema 136 (2.3%) 14 (9.7%)  
Cardiogenic shock 251 (4.2%) 17 (11.8%)  
LV systolic function 
  
0.21 
Good 2750 (50.8%) 58 (43.6%)  
Moderate 1704 (31.5%) 50 (37.6%)  
Poor 421 (7.8%) 14 (10.5%)  
Not assessed 539 (10.0%) 11 (8.3%)  
Comorbidities 
   
Percutaneous coronary intervention 1265 (22.0%) 31 (21.8%) 0.96 
Coronary artery bypass graft 303 (5.4%) 11 (7.9%) 0.22 
Heart failure 542 (9.6%) 20 (14.6%) 0.05 
Hypercholesterolemia 2949 (49.5%) 72 (51.1%) 0.72 
Angina 812 (14.6%) 14 (10.4%) 0.17 
Cerebrovascular disease 361 (6.4%) 15 (10.8%) 0.03 
Myocardial infarction  1412 (24.4%) 42 (29.8%) 0.14 
Peripheral vascular disease 282 (5.0%) 14 (10.1%) 0.007 
Chronic kidney disease 274 (4.9%) 22 (16.1%) <0.001 
Diabetes   <0.001 
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Not diabetic  4716 (75.5%) 91 (60.7%)  
Diet controlled 274 (4.4%) 6 (4.0%)  
Oral medications 872 (14.0%) 33 (22.0%)  
Insulin therapy 384 (6.1%) 20 (13.3%)  
Hypertension 3678 (60.2%) 104 (71.7%) 0.005 
Smoking status 
  
0.02 
Never smoked 2462 (38.3%) 66 (46.2%)  
Previous smoker 2040 (31.7%) 49 (34.3%)  
Current smoker 1934 (30.0%) 28 (19.6%)  
Asthma / COPD 765 (13.7%) 18 (13.3%) 0.90 
Family history of CHD 1542 (31.8%) 28 (26.2%) 0.21 
In-hospital Pharmacology 
   
Low molecular weight heparin 1867 (43.2%) 39 (42.4%) 0.88 
Unfractionated heparin  2092 (47.2%) 34 (36.2%) 0.03 
Warfarin 98 (2.2%) 5 (5.4%) 0.04 
Loop Diuretic 676 (15.6%) 31 (33.7%) <0.001 
Glycoprotein IIbIIIa inhibitor use 1015 (20.7%) 32 (27.6%) 0.07 
Discharge Pharmacology  
   
Aspirin  6226 (98.2%) 138 (97.9%) 0.76 
Any P2Y12 Inhibitor 6013 (97.3%) 121 (92.4%) <0.001 
Dual Antiplatelet medications 5827 (95.6%) 116 (89.9%) 0.002 
Statin 5645 (97.6%) 107 (95.5%) 0.17 
ACEi / ARB 5391 (93.1%) 110 (94.0%) 0.70 
Processes of Care and Clinical 
outcomes 
   
Referral for cardiac Rehabilitation  5068 (86.3%) 84 (64.1%) <0.001 
Cardiology follow up 4662 (93.3%) 87 (89.7%) 0.16 
In-hospital mortality  180 (2.8%) 19 (14.0%) <0.001 
30-day mortality  260 (4.1%) 44 (30.8%) <0.001 
 
 
Table 3: Angiographic characteristics and procedural outcomes of COVID19 ACS patients 
compared to non COVID19 ACS patients undergoing PCI in the BCIS registry  
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Variables 
Non COVID19 AMI 
N=6708 
COVID19 AMI 
N= 157 
 
P value* 
 
Procedural characteristics     
Arterial blood gas PH 7.2 (0.2) 7.3 (0.1)  
Base excess -2.6 (6.25) -2.55 (6.9) <0.001 
Glasgow come scale   0.007 
GCS<8 132 (27.8%) 2 (25.0%)  
GCS ≥8  342 (72.2%) 6 (75.0%)  
Mechanical ventilation 113 (16.4%) 5 (35.7%) 0.05 
Lesion attempted   0.35 
0 186 (2.8%) 4 (2.6%)  
1 4644 (70.2%) 101 (65.6%)  
2 1331 (20.1%) 33 (21.4%)  
3 or more 455 (6.9%) 16 (10.4%)  
Vessel attempted    
Grafts 138 (2.0%) 5 (3.2%) 0.32 
LMS 285 (4.2%) 13 (8.3%) 0.01 
RCA 2338 (34.8%) 54 (34.6%) 0.95 
LAD 3271 (48.8%) 83 (53.2%) 0.27 
LCX 1601 (23.9%) 33 (21.2%) 0.43 
Multi-vessel PCI 992 (14.8%) 31 (19.9%) 0.07 
Number of stents   0.12 
0 886 (13.5%) 19 (12.3%)  
1 3462 (52.6%) 77 (50.0%)  
2 1527 (23.2%) 32 (20.8%)  
3 or more 711 (10.8%) 26 (16.9%)  
Inotropic support 128 (2.0%) 7 (4.8%) 0.01 
Intra-aortic balloon pump 48 (0.8%) 4 (2.8%) 0.006 
TIMI flow post PCI    0.31 
0 146 (3.2%) 1 (1.0%)  
1 41 (0.9%) 0 (0.0%)  
2 175 (3.8%) 6 (6.0%)  
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3 4209 (92.1%) 93 (93.0%)  
IVUS use 639 (11.9%) 24 (16.9%) 0.07 
OCT use 191 (3.9%) 1 (0.8%) 0.08 
FFR/iFR use 419 (8.2%) 2 (1.7%) 0.01 
Procedural outcomes     
MACCE 201 (3.1%) 14 (9.4%) <0.001 
In-hospital death  180 (2.8%) 19 (14.0%) <0.001 
30 day mortality  260 (4.1%) 44 (30.8%) <0.001 
 
Figure 1: Daily cases of COVID19 ACS hospitalized during the study period  
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Figure 2: In hospital outcomes and 30-day mortality of COVID19 ACS patient compared to 
non COVID19 ACS patients 
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Figure 3: Independent predictors of 30-day mortality in COVID positive AMI patients  
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